Combining TRAIL with PD1 inhibitors can effectively block the PD1/PDL1 checkpoint signals, reactivating impotent tumor-specific CD8+ T cells and initiating an immune response through immunogenic cancer cell death [100]. The gene discussed is CD8A; the disease is cancer.